摘要
目的:检测NY-ESO-1蛋白在舌鳞癌(tongue squamous cell carcinoma,TSCC)中的表达情况,分析其与肿瘤临床病理参数的关系,并探讨其作为TSCC免疫治疗靶标的可能性。方法:采用免疫组织化学EnVision法检测53例TSCC标本及10例正常舌黏膜中NY-ESO-1蛋白的表达,SPSS统计软件分析所得数据。结果:53例TSCC标本中13例NY-ESO-l阳性表达(24.5%),定位于细胞浆,而10例正常舌黏膜无表达。NY-ESO-1蛋白的表达与肿瘤大小及临床病理分级有关(P<0.05),但与肿瘤浸润深度及有无淋巴结转移无关。结论:NY-ESO-1蛋白在中高分化TSCC组织中的表达较高,可以进一步研究其作为TSCC免疫治疗靶点的可行性。
Objective： To detect the expression of cancer-testis antigen NY-ESO-1 in human tongue squamous cell carcinoma（TSCC）,and to analyze its expression patterns with clinicopathologic parameters and explore it as a possible therapeutic targets immune of TSCC.Methods： Immunohistochemical EnVision techniques was used to analyze the NY-ESO-1 expression in 53 cases of TSCC and 10 cases of normal tongue mucosa.Statistical analysis was done with SPSS.Results： Expression of NY-ESO-1 was observed in 13 cases of 53 samples（24.5%）,but none in normal tongue mucosa.The expression of NY-ESO-1 was significantly associated with pathological grade and tumor size,but not with positive lymph node status and tumor infiltration depth.Conclusion： The higher expression of NY-ESO-1 in the well differentiated TSCC takes a possibility to explore it as a therapeutic targets immune of TSCC.
出处
《口腔医学研究》
CAS
CSCD
北大核心
2011年第11期978-980,983,共4页
Journal of Oral Science Research
作者简介
张行炜（1985～），男，江西赣州人，硕士，主要从事口腔颌面肿瘤的研究。
通讯作者黄辉，E—mail：huanghui1965@126．com
